Nieuws Regulated Transparency/Denominator Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC EN NL juni 23, 2023
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas EN NL juni 22, 2023
Nieuws Regulated Transparency/Denominator Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC EN NL juni 16, 2023
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas EN NL juni 15, 2023
General Nieuws Oxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the Funding Program with Atlas Special Opportunities LLC EN juni 15, 2023
Nieuws Regulated Transparency/Denominator Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC EN NL juni 12, 2023
General Nieuws Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema EN juni 12, 2023
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS EN NL juni 9, 2023
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS EN NL juni 6, 2023
Nieuws Regulated Oxurion Announces Results of the Extraordinary Shareholders’ Meeting of 22 May 2023 EN NL juni 5, 2023
Nieuws Regulated Transparency/Denominator Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC EN NL juni 1, 2023
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS EN NL mei 31, 2023
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS EN NL mei 26, 2023
General Nieuws Regulated Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema EN mei 25, 2023
General Nieuws Oxurion Issues EUR 2.0 million in Bonds for Tranche 2 of the Funding Program with Atlas Special Opportunities LLC EN mei 22, 2023
Nieuws Regulated Transparency/Denominator Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC EN NL mei 19, 2023
General Nieuws Regulated Oxurion Announces Results of the Annual Shareholders’ Meeting of 2 May 2023 EN mei 15, 2023
Nieuws Regulated Transparency/Denominator Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS EN NL mei 12, 2023
Nieuws Regulated Transparency/Denominator Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC EN NL mei 12, 2023
